53374-52-0

Basic information

• Product Name: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI);4-NITROSO-3,4-DIHYDROQUINOXALIN-2(1H)-ONE
• CAS NO: 53374-52-0
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16
• Product Categories: PIPERIDINE
• Mol File: 53374-52-0.mol

Chemical Properties

• Boiling Point: 447.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.48±0.1 g/cm3(Predicted)
• PKA: 12.20±0.20(Predicted)
• CAS DataBase Reference: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(53374-52-0)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,3,4-dihydro-4-nitroso-(9CI)(53374-52-0)

Safety Data

• Hazardous Substances Data: 53374-52-0(Hazardous Substances Data)

Usage

Structure

A quinoxaline derivative with a nitroso group

Potential use

As a building block in the synthesis of various organic compounds

Biological activity

The nitroso group has potential biological activity

Interest in industries

Pharmaceutical and medicinal chemistry

Ongoing research

Further research and exploration into its properties and potential applications are being conducted.

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 7647-01-0 hydrogenchloride 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 

Downstream Products

• 313368-91-1 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido-[3’,4’:4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1187020-80-9 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt 
• 313368-95-5 4-((6bR,10aS)-3-benzyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 1576239-54-7 4-((6bR,10aS)-3-butyl-2,3,6b,9,10,10ahexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-94-4 4-((6bR,10aS)-3-isopropyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-93-3 4-((6bR,10aS)-3-ethyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone 
• 313368-92-2 4-((6bS,10aR)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one 
• 1576239-87-6 (6bR,10aS)-8-[(3-(4-fluorophenyl)-4,5-dihydroisoxazol-5-yl)methyl]-3-methyl-2,3,6b,7,8,9,10,10aoctahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline 
• 1576239-84-3 4-fluoro-N-[2-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)ethyl]benzamide 

Relevant articles and documents

Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders

We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl) -1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.

FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE

This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4- b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.